Marino Stram & Associates’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Marino Stram & Associates’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-165	Closed	-$16K	–	668
2018 Q3	$16K	Hold	165	–	–	0.01%	265
2018 Q2	$16K	Hold	165	–	–	0.01%	267
2018 Q1	$14K	Buy	+165	New	+$15.1K	0.01%	287

Other funds holding XBI

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Marino Stram & Associates's XBI Position: Q4 2018 in Review

Marino Stram & Associates sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2018, closing a stake of 165 shares — an estimated $16K sold.

Marino Stram & Associates first reported a position in XBI in Q1 2018 and held it in 3 quarters. The position peaked at $16K in Q3 2018. 427 funds tracked by Wall St. Rank hold XBI as of Q4 2018.

Marino Stram & Associates reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2018 after selling out during the quarter.
Marino Stram & Associates sold 165 State Street SPDR S&P Biotech ETF shares in Q4 2018, an estimated $16K.
Marino Stram & Associates first reported a position in State Street SPDR S&P Biotech ETF in Q1 2018 and held it in 3 quarters.
Marino Stram & Associates's State Street SPDR S&P Biotech ETF position peaked at $16K in Q3 2018.
427 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2018.

Based on Marino Stram & Associates's 13F filing for Q4 2018, filed 14 Feb 2019.